Pharmacometabolomics identifies dodecanamide and leukotriene B4 dimethylamide as a predictor of chemosensitivity for patients with acute myeloid leukemia treated with cytarabine and anthracycline

Clinical responses to standard cytarabine plus anthracycline regimen in acute myeloid leukemia (AML) are heterogeneous and there is an unmet need for biological predictors of response to this regimen. Here, we applied a pharmacometabolomics approach to identify potential biomarkers associated with r...

Descripción completa

Detalles Bibliográficos
Autores principales: Tan, Guangguo, Zhao, Bingbing, Li, Yanqing, Liu, Xi, Zou, Zhilan, Wan, Jun, Yao, Ye, Xiong, Hong, Wang, Yanyu
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2017
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5687638/
https://www.ncbi.nlm.nih.gov/pubmed/29179468
http://dx.doi.org/10.18632/oncotarget.20733

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5687638/
https://www.ncbi.nlm.nih.gov/pubmed/29179468
http://dx.doi.org/10.18632/oncotarget.20733

Ejemplares similares